Search - tctmd.com

Displaying 81 - 100 of 763

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2023

Shelley Wood

July 31, 2023

News Daily News

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

L.A. McKeown

July 11, 2023

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

L.A. McKeown

June 21, 2023

News Conference News LINC 2023

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

L.A. McKeown

June 07, 2023

News Industry News

Concept Medical’s fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA)

June 01, 2023

News Daily News

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Michael O'Riordan

February 24, 2023

News Daily News

Top Endovascular News of 2022

L.A. McKeown

January 03, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

L.A. McKeown

November 07, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

Presentation TCT 2022

Sustained Limus Release vs Paclitaxel DCB Treatment in Symptomatic Peripheral Artery Disease: The Limus FLOW Investigator-Initiated, Randomized Controlled Trial

Presenter: Christos Rammos

September 17, 2022

Presentation TCT 2022

Have We Gotten to the Final Word on Paclitaxel Safety?

Presenter: Eric Secemsky

September 17, 2022

Presentation TCT 2022

3-Year Outcome of paclitaxel DCB vs. DES for Native Vessel Disease Treatment: Final Follow Up of the Randomized PICCOLETO II Trial

Presenter: Bernardo Cortese

September 17, 2022

News Industry News

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

September 13, 2022

Podcast TCTMD Talking Points

Two DCBs Go Head to Head in De Novo CAD

August 24, 2022

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2022

Caitlin E. Cox

July 04, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News SCAI 2022

SAFE-PAD Provides More Long-term Safety Data for Paclitaxel

L.A. McKeown

May 22, 2022

Presentation ARCH 2022

Paclitaxel or Limus: What is the Future in Drug Eluting Therapies?

Presenter: Craig M. Walker

April 23, 2022

Advertisement

TCTMD’s Top 10 Most Popular Stories for July 2023

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

Concept Medical’s fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA)

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Top Endovascular News of 2022

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

Sustained Limus Release vs Paclitaxel DCB Treatment in Symptomatic Peripheral Artery Disease: The Limus FLOW Investigator-Initiated, Randomized Controlled Trial

Have We Gotten to the Final Word on Paclitaxel Safety?

3-Year Outcome of paclitaxel DCB vs. DES for Native Vessel Disease Treatment: Final Follow Up of the Randomized PICCOLETO II Trial

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

Two DCBs Go Head to Head in De Novo CAD

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

TCTMD’s Top 10 Most Popular Stories for June 2022

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

SAFE-PAD Provides More Long-term Safety Data for Paclitaxel

Paclitaxel or Limus: What is the Future in Drug Eluting Therapies?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content